1. U.S. Food and Drug Administration. FDA approves new oral therapy to treat ALK-positive lung cancer. FDA News Release. [2015 Dec 11; cited 2016 Mar 22]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm.
2. U.S. Food and Drug Administration. FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer. FDA News Release. [2016 Mar 11; cited 2016 Mar 22]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm490329.htm.
3. Genentech. U.S. prescribing information for Alecensa (alectinib) capsules, for oral use [Internet]. Revised 12 2015 [cited 2016 Mar 31]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf.
4. Pfizer. U.S. prescribing information for Xalkori (crizotinib) capsules, for oral use [Internet]. Revised 3 2016 [cited 2016 Mar 31]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s016lbl.pdf.
5. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer